Chapman, Kenneth R. http://orcid.org/0000-0002-2498-9859
Wise, Robert A.
Scirica, Benjamin M.
Bhatt, Deepak L.
Daoud, Sami Z.
Lythgoe, Dan
Gil, Esther Garcia
Clinical trials referenced in this document:
Documents that mention this clinical trial
Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers
https://0-doi-org.brum.beds.ac.uk/10.1186/s12931-021-01861-2
Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial
https://0-doi-org.brum.beds.ac.uk/10.1007/s12325-021-01878-5
Funding for this research was provided by:
Forest Laboratories
AstraZeneca
Article History
Received: 12 March 2021
Accepted: 8 October 2021
First Online: 22 October 2021
Declarations
:
: The trial protocol and informed consent procedures were approved by the institutional review board with controlling authority at each study site. All patients provided written informed consent prior to the conduct of any study-specific procedures. The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines.
: Not applicable.
: KRC received personal fees from AstraZeneca, Boehringer Ingelheim, CIHR-GSK Research Chair in Respiratory Health Care Delivery (UHN), CSL Behring, Genentech, Grifols, Kamada, Merck, Novartis, Roche, and Sanofi; and grants from Amgen, AstraZeneca, Baxter, Boehringer Ingelheim, CSL Behring, Genentech, Grifols, GlaxoSmithKline, Kamada, Novartis, Roche, Sanofi, and Shire, during the conduct of the study. RAW received personal fees from AstraZeneca, during the conduct of the study; personal fees from AbbVie, AnaptysBio, AstraZeneca/MedImmune, Circassia, ContraFect, Galderma, GlaxoSmithKline, Kamada, Kinevant, Kiniksa, Merck, Novartis, Pneuma, Propeller Health, Pulmonx, Roche, Sunovion, and Verona; and grants from AstraZeneca/MedImmune, Boehringer Ingelheim, and Pearl Therapeutics, outside of the submitted work. BMS received an Institutional research grant to Brigham and Women’s Hospital from AstraZeneca during the conduct of the study; consulting fees from AbbVie, Allergan, AstraZeneca, Boehringer Ingelheim, Eisai, Elsevier Practice Update Cardiology, Esperion, Hanmi, Lexicon, Medtronic, Merck, and Novo Nordisk; equity in Health[at]Scale; and grants from Eisai, Merck, Novartis, Novo Nordisk, and Pfizer, outside of the submitted work. DLB discloses the following relationships—Advisory Board: Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic, The Medicines Company, 89Bio; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Takeda. SZD is an employee of AstraZeneca. DL is an employee of Phastar and former consultant statistician to AstraZeneca. EGG was an employee and shareholder of AstraZeneca at the time of the study and is now an employee of Almirall S.A., Barcelona, Spain.